Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing.
Moderna rose 11%; Novavax and others, including Inovio Pharmaceuticals (INO), CureVac (NASDAQ:CVAC), and Arcturus Therapeutics (NASDAQ:ARCT), also traded significantly higher. Manufacturers of the COVID-19 vaccination Comirnaty, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), noted more meager increases.
Based on last week's U.S. Centers for Disease Control and Prevention (CDC) data showing increasing COVID-19 activity in most areas and a concurrent rise in seasonal flu, especially among small children, the rally followed last week's Citing their success in lowering serious disease and hospitalization, the CDC advised Americans to get recommended vaccinations.
The organization also underlined how common respiratory syncytial virus (RSV) is in young children. With its mREVIA medicine, Moderna has joined Pfizer's Abysvo and GSK's Arexvy vaccines on the RSV vaccination market. As health authorities stress preventative actions, the increasing need for vaccinations to treat certain respiratory diseases has attracted investment attention in the sector.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。